End-stage renal disease: Sudden cardiac death: Stratifying risk in dialysis patients

Nature Reviews Nephrology

Volumn 7, Issue 3, 2011, Pages 133-135

  Passman, Rod ^a   Herzog, Charles A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER;

CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEFIBRILLATOR; ECHOCARDIOGRAPHY; HEART DEATH; HEMODIALYSIS PATIENT; HUMAN; MORBIDITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; STRATIFIED SAMPLE; SUDDEN DEATH;

DEATH, SUDDEN, CARDIAC; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 79952242225     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.166     Document Type: Short Survey

References (10)

1. Us Renal Data system. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, national institutes of Health, national institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, UsA (2010).
2. Us Renal Data system. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, national institutes of Health, national institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, UsA (2007).
3. wang, A. Y. et al. sudden cardiac death in endstage renal disease patients: A 5-year prospective analysis. Hypertension 56, 210-216 (2010).
4. Herzog, C. A. et al. sudden cardiac death and dialysis patients. Semin. Dial. 21, 300-307 (2008).
5. Moss, A. J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction (Pubitemid 34984635)
6. Bardy, G. H. et al. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005). (Pubitemid 40110811)
7. Apple, F. s. et al. Predictive value of cardiac troponin i and T for subsequent death in endstage renal disease. Circulation 106, 2941-2945 (2002). (Pubitemid 35424746)
8. Myerburg, R. J. et al. interpretation of outcomes of antiarrhythmic clinical trials: Design features and population impact. Circulation 97, 1514-1521 (1998). (Pubitemid 28191308)
9. Cice, G. et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebocontrolled trial. J. Am. Coll. Cardiol. 41, 1438-1444 (2003). (Pubitemid 36543357)
10. epstein, A. e. et al. ACC/AHA/HRs 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the ACC/AHA/nAsPe 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic surgery and society of Thoracic surgeons. J. Am. Coll. Cardiol. 51, 1-62 (2008).